Uric acid as prognostic marker in advanced nonischemic dilated cardiomyopathy: Comparison with N-terminal pro B-type natriuretic peptide level

Congestive Heart Failure

Volumn 16, Issue 4, 2010, Pages 153-158

  Kim, Hyungseop ^a   Shin, Hong Won ^a   Son, Jihyun ^a   Yoon, Hyuck Jun ^a   Park, Hyoung Seob ^a   Cho, Yun Kyeong ^a   Han, Choon Duk ^a   Nam, Chang Wook ^a   Hur, Seung Ho ^a   Kim, Yoon Nyun ^a   Kim, Kwon Bae ^a  

^a Dongsan Medical Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; URIC ACID;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONGESTIVE CARDIOMYOPATHY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NONISCHEMIC DILATED CARDIOMYOPATHY; PRIORITY JOURNAL; PROGNOSIS;

BIOLOGICAL MARKERS; CARDIOMYOPATHY, DILATED; CONFIDENCE INTERVALS; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HEALTH STATUS INDICATORS; HEMODYNAMICS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; STATISTICS AS TOPIC; URIC ACID;

EID: 77955138299     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2010.00144.x     Document Type: Article

References (28)

1. Cheng V, Kazanagra R, Garcia A. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol. 2001, 37:386-391.
2. Maeda K, Tsutamoto T, Wada A. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol. 2000, 36:1587-1593.
3. Iwashima Y, Horio T, Kamide K. Uric acid, left ventricular mass index, and risk of cardiovascular disease in essential hypertension. Hypertension. 2006, 47:195-202.
4. Alderman MH. Uric acid and cardiovascular risk. Curr Opin Pharmacol 2002, 2:126-130.
5. Niizeki T, Takeishi Y, Arimoto T. Hyperuricemia associated with high cardiac event rates in the elderly with chronic heart failure. J Cardiol. 2006, 47:219-228.
6. Anker SD, Rauchhaus M. Heart failure as a metabolic problem. Eur J Heart Fail. 1999, 1:127-131.
7. Cappola TP, Kass DA, Nelson GS. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation. 2001, 104:2407-2411.
8. Levey AS, Bosch JP, Lewis JB. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999, 130:461-470.
9. Leyva F, Anker S, Swan JW. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J. 1997, 18:858-865.
10. Hare JM, Johnson RJ. Uric acid predicts clinical outcomes in heart failure: insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology. Circulation. 2003, 107:1951-1953.
11. Pascual-Figal DA, Hurtado-Martinez JA, Redondo B. Hyperuricaemia and long-term outcome after hospital discharge in acute heart failure patients. Eur J Heart Fail. 2007, 9:518-524.
12. Johnson RJ, Rodriguez-Iturbe B, Kang DH. A unifying pathway for essential hypertension. Am J Hypertens 2005, 18:431-440.
13. Ruggiero C, Cherubini A, Ble A. Uric acid and inflammatory markers. Eur Heart J. 2006, 27:1174-1181.
14. de Jong JW, Schoemaker RG, de Jonge R. Enhanced expression and activity of xanthine oxidoreductase in the failing heart. J Mol Cell Cardiol. 2000, 32:2083-2089.
15. Hamada T, Ichida K, Hosoyamada M. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am J Hypertens. 2008, 21:1157-1162.
16. Reyes AJ, Leary WP. Hypertension, diuretics, and uric acid. Am J Hypertens. 2006, 19:1093-1094.
17. Steele TH. Control of uric acid excretion. N Engl J Med. 1971, 284:1193-1196.
18. Kurata A, Shigematsu Y, Higaki J. Sex-related differences in relations of uric acid to left ventricular hypertrophy and remodeling in Japanese hypertensive patients. Hypertens Res. 2005, 28:133-139.
19. Selby JV, Friedman GD, Quesenberry CP. Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries. Am J Epidemiol. 1990, 131:1017-1027.
20. Jossa F, Farinaro E, Panico S. Serum uric acid and hypertension: the Olivetti heart study. J Hum Hypertens. 1994, 8:677-681.
21. Packer M. Should B-type natriuretic peptide be measured routinely to guide the diagnosis and management of chronic heart failure? Circulation. 2003, 108:2950-2953.
22. Sun T, Wang L, Zhang Y. Prognostic value of B-type natriuretic peptide in patients with chronic and advanced heart failure. Intern Med J. 2007, 37:168-171.
23. Duan X, Ling F. Is uric acid itself a player or a bystander in the pathophysiology of chronic heart failure? Med Hypotheses. 2008, 70:578-581.
24. Cicoira M, Zanolla L, Rossi A. Elevated serum uric acid levels are associated with diastolic dysfunction in patients with dilated cardiomyopathy. Am Heart J. 2002, 143:1107-1111.
25. Giamouzis G, Kalogeropoulos AP, Georgiopoulou VV. Incremental value of renal function in risk prediction with the Seattle Heart Failure Model. Am Heart J. 2009, 157:299-305.
26. Cauthen CA, Lipinski MJ, Abbate A. Relation of blood urea nitrogen to long-term mortality in patients with heart failure. Am J Cardiol. 2008, 101:1643-1647.
27. Filippatos G, Rossi J, Lloyd-Jones DM. Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: insights from the Acute and Chronic Theraputic Impact of a Vasopressin Antagonist in Chronic Heart Faiure (ACTIV in CHF) study. J Card Fail. 2007, 13:360-364.
28. Ronco C, Haapio M, House AA. Cardiorenal syndrome. J Am Coll Cardiol. 2008, 52:1527-1539.